Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
135,286
-100.0%
|
-
|
|
Dec 18
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
21,562
+50.0%
|
-
|
|
Dec 18
2024
|
Michael Hatzfeld Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,676
-100.0%
|
-
|
|
Dec 18
2024
|
Michael Hatzfeld Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,144
+50.0%
|
-
|
|
Dec 18
2024
|
David Mc Erlane Group President, Biologics |
SELL
Sale (or disposition) back to the issuer
|
Direct |
47,730
-100.0%
|
-
|
|
Dec 18
2024
|
David Mc Erlane Group President, Biologics |
BUY
Grant, award, or other acquisition
|
Direct |
11,426
+50.0%
|
-
|
|
Dec 18
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Sale (or disposition) back to the issuer
|
Direct |
52,573
-100.0%
|
-
|
|
Dec 18
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
12,938
+50.0%
|
-
|
|
Dec 18
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
38,232
-100.0%
|
-
|
|
Dec 18
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
14,265
+50.0%
|
-
|
|
Dec 18
2024
|
Jack L Stahl |
SELL
Sale (or disposition) back to the issuer
|
Direct |
47,984
-100.0%
|
-
|
|
Dec 18
2024
|
Michelle R Ryan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,835
-100.0%
|
-
|
|
Dec 18
2024
|
Donald E Morel Jr |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,118
-100.0%
|
-
|
|
Dec 18
2024
|
Stephanie Okey |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,635
-100.0%
|
-
|
|
Dec 18
2024
|
Frank A Damelio |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,635
-100.0%
|
-
|
|
Dec 18
2024
|
Gregory T Lucier |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,914
-100.0%
|
-
|
|
Dec 18
2024
|
Steven Barg |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,374
-100.0%
|
-
|
|
Dec 18
2024
|
J Martin Carroll |
SELL
Sale (or disposition) back to the issuer
|
Direct |
32,734
-100.0%
|
-
|
|
Dec 18
2024
|
Rolf A Classon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
47,984
-100.0%
|
-
|
|
Dec 18
2024
|
Michael J Barber |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,052
-100.0%
|
-
|
|
Dec 18
2024
|
Lisa Evoli SVP, Chief HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,398
-100.0%
|
-
|
|
Dec 18
2024
|
Lisa Evoli SVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,032
+50.0%
|
-
|
|
Dec 18
2024
|
John J Greisch Executive Chair |
SELL
Sale (or disposition) back to the issuer
|
Direct |
113,462
-100.0%
|
-
|
|
Dec 18
2024
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
33,530
+50.0%
|
-
|
|
Dec 18
2024
|
John J Greisch Executive Chair |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
34,000
-100.0%
|
-
|
|
Dec 18
2024
|
Matti Masanovich SVP, Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
148,166
-100.0%
|
-
|
|
Dec 18
2024
|
Matti Masanovich SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,691
+50.0%
|
-
|
|
Dec 18
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,696
-100.0%
|
-
|
|
Dec 18
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
10,722
+50.0%
|
-
|
|
Dec 18
2024
|
Alessandro Maselli President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
290,745
-100.0%
|
-
|
|
Dec 18
2024
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
113,224
+50.0%
|
-
|
|
Nov 11
2024
|
Michelle R Ryan |
SELL
Open market or private sale
|
Direct |
2,800
-20.54%
|
$165,200
$59.7 P/Share
|
|
Oct 30
2024
|
Michelle R Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+25.48%
|
-
|
|
Oct 30
2024
|
Steven Barg |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+27.37%
|
-
|
|
Oct 30
2024
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+26.96%
|
-
|
|
Oct 30
2024
|
Michael J Barber |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+20.53%
|
-
|
|
Oct 30
2024
|
Frank A Damelio |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+26.96%
|
-
|
|
Oct 30
2024
|
Donald E Morel Jr |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+6.24%
|
-
|
|
Oct 30
2024
|
J Martin Carroll |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+12.47%
|
-
|
|
Oct 30
2024
|
Gregory T Lucier |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+11.22%
|
-
|
|
Oct 30
2024
|
Rolf A Classon |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+8.86%
|
-
|
|
Oct 30
2024
|
Jack L Stahl |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+8.86%
|
-
|
|
Oct 18
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
SELL
Open market or private sale
|
Direct |
320
-1.32%
|
$18,880
$59.97 P/Share
|
|
Sep 26
2024
|
David Mc Erlane Group President, Biologics |
SELL
Open market or private sale
|
Direct |
1,994
-5.21%
|
$117,646
$59.97 P/Share
|
|
Aug 02
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
662
-2.16%
|
$39,058
$59.56 P/Share
|
|
Aug 02
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
666
-1.65%
|
$39,294
$59.55 P/Share
|
|
Aug 02
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
SELL
Open market or private sale
|
Direct |
608
-2.44%
|
$35,872
$59.58 P/Share
|
|
Aug 02
2024
|
Lisa Evoli SVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
3,859
-8.93%
|
$227,681
$59.67 P/Share
|
|
Aug 02
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
1,169
-1.02%
|
$68,971
$59.55 P/Share
|
|
Jul 29
2024
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
9,088
-4.87%
|
$527,104
$58.76 P/Share
|